SABCS 2023 HR+/HER2- MBC

CDK4/6 Inhibitors in HER2-low Metastatic Breast Cancer

HER2 gene amplification may have impact on CDK 4/6 inhibitor-therapy effectiveness in patients with metastatic breast cancer. Read More ›

Ribociclib Plus Endocrine Therapy Found to Improve Progression-Free Survival and Overall Survival in Elderly Patients

SABCS 2023 HR+/HER2- MBC

Pooled analysis of the MONALEESA-2, -3, and -7 clinical trials finds elderly patients have survival benefits from treatment with ribociclib plus endocrine therapy. Read More ›

Clinical Meaningfulness Poorly Understood and Often Not Considered in the Metastatic Breast Cancer Clinical Setting

SABCS 2023 HR+/HER2- MBC

Focus group analysis of stakeholders in metastatic breast cancer treatment finds a need for accessible and patient-friendly terminology in metastatic breast cancer treatment-making discussions. Read More ›

CDK4/6 Inhibitors Plus Radiotherapy for Patients With HR+/HER2– Advanced Breast Cancer With Brain Metastases

SABCS 2023 HR+/HER2- MBC

The use of CDK4/6 inhibitors following radiotherapy demonstrated to be safe and effective in patients with HR+/HER2– advanced breast cancer who develop brain metastases. Read More ›

First-Line Treatment Sequencing Associated With an Improved Progression-Free Survival in Patients With Metastatic Breast Cancer

SABCS 2023 HR+/HER2- MBC

Recent retrospective study finds that receiving CDK4/6 inhibitor plus endocrine therapy improves progression-free survival in patients with HR+/HER2– metastatic breast cancer. Read More ›

SABCS 2023 HR+/HER2- MBC

Page 2 of 2